Cronos Group received a C$2.4 billion strategic investment from Altria, the tobacco company, which gave Altria an approximate 45% ownership stake, making Cronos one of the few cannabis companies backed by a global tobacco company rather than a typical venture or private equity investor. Cronos also partnered with Ginkgo Bioworks to produce cannabinoids using synthetic biology instead of relying only on plant extraction, later launching its first cultured cannabinoid product, while its PEACE NATURALS brand remained the top cannabis brand for medical patients in Israel through 2025 and expanded to seven medical markets, including Australia, Switzerland, and Malta.